Veröffentlichungen
Wissenschaftliche Publikationen
Der wissenschaftliche Hintergrund unserer Arbeit ist in begutachteten Fachzeitschriften dokumentiert. Aufgeführt sind die 60 aktuellsten Arbeiten von Prof. Dr. med. Samer Ezziddin und seinem Team; jeder Eintrag verweist auf den Originaleintrag in PubMed.
- September 2026
Organ and tumor dosimetry of [(161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC
Schaefer-Schuler A, Blickle A, Ganz S, Petto S, Burgard C, Speicher T et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - August 2026
Diagnosis of Extra-Skeletal Ewing Sarcoma in an 11-Year-Old Child with Large Thoracic Mass revealed by [(18)F]FDG PET/CT
Rosar F, Bastian MB, Burgard C, Remke M, Collaud S, Kaman H et al.
Nuclear medicine and molecular imaging
Zur Veröffentlichung - Juli 2026
Real-world evaluation of [(177)Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort
Misirci M, Rosar F, Khreish F, Burgard C, Blickle A, Bartholomä M et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Juni 2026
Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model Performance
Speicher T, Demirkol IE, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A et al.
Current oncology (Toronto, Ont.)
Zur Veröffentlichung - Juni 2026
Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617
Rosar F, Burgard C, Hoang SPT, Blickle A, Bartholomä M, Maus S et al.
Clinical nuclear medicine
Zur Veröffentlichung - Juli 2026
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study
Speicher T, Latell S, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Juni 2026
FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?
Bastian MB, Kyriakou I, Rosar F, Blickle A, Burgard C, Speicher T et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Zur Veröffentlichung - März 2026
Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
Ebert N, Rosar F, Burgard C, Bartholomä M, Maus S, Hein C et al.
EJNMMI research
Zur Veröffentlichung - Februar 2026
Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression
Khreish F, Rosar F, Burgard C, Petto S, Maus S, Stemler T et al.
EJNMMI research
Zur Veröffentlichung - Februar 2026
Auger Emitting [(161)Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis
Rosar F, Blickle A, Bastian MB, Speicher T, Schaefer-Schuler A, Burgard C et al.
Nuclear medicine and molecular imaging
Zur Veröffentlichung - April 2026
Comparison of mCRPC [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting
Rosar F, Khreish F, Burgard C, Fursov A, Blickle A, Bartholomä M et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - 2025
Advancing patient education in PRRT through large language models: challenges and potential
Speicher T, Bastian MB, Blickle A, Atzinger A, Rosar F, Burgard C et al.
American journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - 2025
Pilot experience of [(161)Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry
Rosar F, Burgard C, Petrescu C, Blickle A, Bartholomä M, Maus S et al.
Theranostics
Zur Veröffentlichung - Dezember 2025
Assessment of scintigraphic imaging with Terbium-161: A visual and quantitative analysis
Rosar F, Petto S, Ganz S, Burgard C, Maus S, Bartholomä M et al.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
Zur Veröffentlichung - Juli 2025
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
Bastian MB, Speicher T, Blickle A, Burgard C, Bastian JLD, Bartholomä M et al.
EJNMMI research
Zur Veröffentlichung - Juni 2025
Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy
Burgard C, Muenzenberg MD, Blickle A, Bartholomä M, Maus S, Petto S et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Zur Veröffentlichung - März 2026
Novel 64 Cu-labeled Trimeric PSMA Ligand Unequivocally Identifies Local Recurrence of Prostate Cancer Ambiguously Imaged by 18 F-DCFPyL PSMA PET/CT
Bartholomä M, Rosar F, Burgard C, Maus S, Schreck MV, Ezziddin S
Clinical nuclear medicine
Zur Veröffentlichung - Juli 2025
Radiochemistry of cyclen-derived chelators comprising five-membered azaheterocyclic arms with (212)Pb(2+), (213)Bi(3+), and (225)Ac(3)
Hierlmeier I, Randhawa P, McNeil BL, Oliveri E, Maus S, Radchenko V et al.
Nuclear medicine and biology
Zur Veröffentlichung - November 2025
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)
Bastian MB, Wörl B, Blickle A, Burgard C, Speicher T, Bartholomä M et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - September 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient Cohort
Bastian MB, Wörl B, Blickle A, Burgard C, Speicher T, Wessendorf J et al.
Clinical nuclear medicine
Zur Veröffentlichung - Oktober 2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007
Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Oktober 2025
Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept
Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S et al.
Clinical nuclear medicine
Zur Veröffentlichung - Januar 2026
Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept
Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S et al.
Clinical nuclear medicine
Zur Veröffentlichung - März 2025
[(18)F]FDG PET/CT of Langerhans Cell Histiocytosis with Vertebra Plana
Speicher T, Bastian MB, Christofyllakis K, Rosar F, Ezziddin S, Burgard C
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - Oktober 2025
[(68)Ga]Ga-FAPI-04 PET/CT in a patient with endometriosis: a potential game changer?
Burgard C, Rosar F, Ezziddin S, Hamoud BH, Solomayer EF, Laschke MW et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - 2025
Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET
Aouf A, Speicher T, Blickle A, Bastian MB, Burgard C, Rosar F et al.
Frontiers in medicine
Zur Veröffentlichung - August 2025
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study
Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - April 2025
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)
Rosar F, Khreish F, Nagel LS, Blickle A, Burgard C, Petto S et al.
Clinical nuclear medicine
Zur Veröffentlichung - Februar 2025
Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT
Bastian MB, Burgard C, Blickle A, Ezziddin S, Rosar F
Clinical nuclear medicine
Zur Veröffentlichung - Dezember 2024
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform
Martin S, Schreck MV, Stemler T, Maus S, Rosar F, Burgard C et al.
EJNMMI radiopharmacy and chemistry
Zur Veröffentlichung - Januar 2025
First Successful In-Human Application of 225Ac-DOTA-LM3 Mono-PRRT for the Treatment of an Otherwise Therapy-Resistant Neuroendocrine Tumor (NET G3)
Speicher T, Burgard C, Bastian M, Rosar F, Bartholomä M, Maus S et al.
Clinical nuclear medicine
Zur Veröffentlichung - März 2025
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia
Bastian MB, Sieben M, Blickle A, Burgard C, Speicher T, Bartholomä M et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Februar 2025
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function
Bastian MB, Sieben M, Burgard C, Blickle A, Speicher T, Bartholomä M et al.
Clinical nuclear medicine
Zur Veröffentlichung - Oktober 2024
Analysis of Molecular Imaging Biomarkers Derived from [(18)F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [(225)Ac]Ac-PSMA-617-Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy
Burgard C, Khreish F, Dahlmanns L, Blickle A, Bastian MB, Speicher T et al.
Cancers
Zur Veröffentlichung - Oktober 2024
[(89)Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [(18)F]PSMA-1007 Imaging
Bastian MB, Burgard C, Blickle A, Speicher T, Ezziddin S, Rosar F
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - Oktober 2024
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [(89)Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer
Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ et al.
Cancer imaging : the official publication of the International Cancer Imaging Society
Zur Veröffentlichung - Oktober 2024
Radiochemistry and Complex Formation of the Cyclen-Derived Chelator DOTI-Me with Mn(2+), Cu(2+), Zn(2+), Ga(3+), In(3+), Tb(3+), and Lu(3)
Hierlmeier I, Marino N, Schreck MV, Schneider L, Maus S, Barrett K et al.
Inorganic chemistry
Zur Veröffentlichung - November 2024
Ectopic Cushing Syndrome Localized by 68 Ga-DOTA-LM3 PET/CT
Bastian MB, Rosar F, Burgard C, Blickle A, Ezziddin S
Clinical nuclear medicine
Zur Veröffentlichung - Juli 2024
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival
Hein C, Burgard C, Blickle A, Bastian MB, Maus S, Schaefer-Schuler A et al.
Cancers
Zur Veröffentlichung - November 2024
Efficacy and safety of rechallenge [(177)Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)
Rosar F, Schuler J, Burgard C, Blickle A, Bartholomä M, Maus S et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Mai 2024
Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [(18)F]FDG PET/CT
Bastian MB, Blickle A, Burgard C, Fleser O, Christofyllakis K, Ezziddin S et al.
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - Juli 2024
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective Registry
Rosar F, Burgard C, Rohloff LV, Blickle A, Bartholomä M, Maus S et al.
Clinical nuclear medicine
Zur Veröffentlichung - Mai 2024
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
Rosar F, Burgard C, David S, Marlowe RJ, Bartholomä M, Maus S et al.
Scientific reports
Zur Veröffentlichung - April 2024
Mind the Pitfall: Solitary Nodular Fasciitis Mimicking Extra-Nodal Manifestation of Hodgkin Lymphoma on [(18)F]FDG PET/CT
Markandu S, Blickle A, Burgard C, Remke M, Altmeyer K, Wagner M et al.
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - 2024
Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves' disease: comparison of conventional versus lithium-augmented radioiodine therapy
Khreish F, Schaefer-Schuler A, Roth L, Burgard C, Rosar F, Ezziddin S
Frontiers in medicine
Zur Veröffentlichung - 2024
[(161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [(177)Lu]Lu-PSMA-617
Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S et al.
Theranostics
Zur Veröffentlichung - Mai 2024
Mast Cell Sarcoma Mimicking Lymphoma or Metastatic Disease on 18 F-FDG PET/CT
Rosar F, Ezziddin S, Bittenbring JT, Christofyllakis K, Burgard C
Clinical nuclear medicine
Zur Veröffentlichung - Februar 2024
[(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis
Rosar F, Burgard C, Larsen E, Khreish F, Marlowe RJ, Schaefer-Schuler A et al.
Cancer imaging : the official publication of the International Cancer Imaging Society
Zur Veröffentlichung - 2023
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
Burgard C, Engler J, Blickle A, Bartholomä M, Maus S, Schaefer-Schuler A et al.
Frontiers in medicine
Zur Veröffentlichung - Januar 2024
Safety and Efficacy of Selective Internal Radionuclide Therapy with (90)Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization
Bellendorf A, Mader N, Mueller SP, Ezziddin S, Bockisch A, Grafe H et al.
Pharmaceuticals (Basel, Switzerland)
Zur Veröffentlichung - Dezember 2023
Active Lumbar Spondylodiscitis on [(68)Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis
Rosar F, Burgard C, Gargiulo R, Ezziddin S
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - Dezember 2023
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent (68)Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me
Schreck MV, Burgard C, Schmidtke A, Hierlmeier I, Stemler T, Maus S et al.
Molecular pharmaceutics
Zur Veröffentlichung - Februar 2024
Change in total lesion PSMA (TLP) during [(177)Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry
Burgard C, Hein C, Blickle A, Bartholomä M, Maus S, Petto S et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Juli 2023
Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - Mai 2023
Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
Burgard C, Rosar F, Marlowe RJ, Bartholomä M, Dewes S, Schaefer-Schuler A et al.
Cancers
Zur Veröffentlichung - Juli 2023
Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S et al.
European journal of nuclear medicine and molecular imaging
Zur Veröffentlichung - April 2023
Histologically Confirmed Testicular Metastasis Revealed by [(89)Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
Rosar F, Burgard C, Linxweiler J, Wagner M, Ezziddin S
Diagnostics (Basel, Switzerland)
Zur Veröffentlichung - Februar 2023
Detection Efficacy of (68)Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience
Burgard C, Hoffmann MA, Frei M, Buchholz HG, Khreish F, Marlowe RJ et al.
Cancers
Zur Veröffentlichung - Mai 2023
New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC
Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S
Clinical nuclear medicine
Zur Veröffentlichung - Dezember 2022
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Banda A, Privé BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC et al.
Cancers
Zur Veröffentlichung